Last reviewed · How we verify
SR121463B
SR121463B is a small molecule that acts as a selective and potent inhibitor of the serotonin 5-HT6 receptor.
SR121463B is a small molecule that acts as a selective and potent inhibitor of the serotonin 5-HT6 receptor. Used for Alzheimer's disease.
At a glance
| Generic name | SR121463B |
|---|---|
| Sponsor | Sanofi |
| Drug class | 5-HT6 receptor antagonist |
| Target | 5-HT6 receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
By blocking the 5-HT6 receptor, SR121463B is expected to increase the levels of acetylcholine in the brain, which may help to improve cognitive function in patients with Alzheimer's disease. This mechanism of action is thought to be beneficial in the treatment of cognitive impairment associated with neurodegenerative diseases.
Approved indications
- Alzheimer's disease
Common side effects
- Headache
- Dizziness
- Nausea
Key clinical trials
- Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS) (PHASE3)
- A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia (PHASE3)
- Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver (PHASE3)
- Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver (PHASE3)
- Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (PHASE3)
- Satavaptan Dose-Ranging Study in the Prevention of Ascites (PHASE2)
- Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites (PHASE2)
- Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SR121463B CI brief — competitive landscape report
- SR121463B updates RSS · CI watch RSS
- Sanofi portfolio CI